{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Torres VE"],"funding":["NCATS NIH HHS","NIDDK NIH HHS","NCRR NIH HHS"],"pagination":["577-85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3580956"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["81(6)"],"pubmed_abstract":["HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m(2). Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m(2). We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher"],"journal":["Kidney international"],"pubmed_title":["Analysis of baseline parameters in the HALT polycystic kidney disease trials."],"pmcid":["PMC3580956"],"funding_grant_id":["M01 RR000051","DK62411","DK62410","RR025008","UL1 TR000454","U01 DK062410","U01 DK062411","RR23940","RR00585","UL1 RR025008","M01 RR000039","U01 DK062408","UL1 RR025780","RR000054","UL1 RR024150","M01 RR000054","RR000051","RR025752","DK62402","DK62401","U01 DK082230","RR000039","RR024989","DK62408","U01 DK062401","U01 DK062402","UL1 RR024989","UL1 RR025752","RR024150","M01 RR000585","M01 RR023940","RR025780"],"pubmed_authors":["Chapman AB","Bost JE","Masoumi A","HALT PKD Study Group","Remer E","Bae KT","Winklhofer FT","Baker D","Kelleher C","Miskulin DC","Otto K","Torres VE","Thompson PA","Maxwell B","Halin NJ","Patel N","Abebe KZ","Hitchcock S","Braun WE","Steinman TI","Perkins L","Spirko R","Pedrosa I","Perrone RD","Flynn G","Martin DR","Woltman R","Watkins D","Fishman M","Ondler H","Jolley A","Erfort A","Glockner J","Smith P","Lanza P","Meyers CM","Wetzel LH","Oskoui FR","Morgan P","Simon G","Hogan MC","Miller JP","Driggs J","Schrier RW"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of baseline parameters in the HALT polycystic kidney disease trials.","description":"HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m(2). Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m(2). We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Mar","modification":"2025-04-18T17:02:55.533Z","creation":"2019-03-26T23:05:23Z"},"accession":"S-EPMC3580956","cross_references":{"pubmed":["22205355"],"doi":["10.1038/ki.2011.411"]}}